QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
NYSE:CANF

Can-Fite BioPharma (CANF) Price Target & Analyst Ratings

$2.59
+0.10 (+4.02%)
(As of 09/26/2023 ET)
Compare
Today's Range
$2.48
▼
$2.62
50-Day Range
$2.49
▼
$3.12
52-Week Range
$1.52
▼
$9.00
Volume
3,038 shs
Average Volume
48,287 shs
Market Capitalization
$9.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media

Can-Fite BioPharma Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 2 Analyst Ratings

Consensus Analyst Price Target

$23.00
788.03% Upside
High Prediction$34.00
Average Prediction$23.00
Low Prediction$12.00
TypeCurrent
9/26/22 to 9/26/23		1 Month Ago
8/27/22 to 8/27/23		3 Months Ago
6/28/22 to 6/28/23		1 Year Ago
9/26/21 to 9/26/22
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
2 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$23.00$23.00$34.00$66.25
Predicted Upside788.03% Upside746.63% Upside1,228.13% Upside441.92% Upside
Get Can-Fite BioPharma Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CANF and its competitors with MarketBeat's FREE daily newsletter.


CANF Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CANF Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Can-Fite BioPharma Stock vs. The Competition

TypeCan-Fite BioPharmaMedical CompaniesS&P 500
Consensus Rating Score
2.50
2.66
2.49
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside827.42% Upside1,376.78% Upside696.59% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Historical Target Prices and Ratings

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/24/2023Alliance Global Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost Target$8.25 ➝ $12.00+296.04%
3/13/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingBuy$34.00+1,228.12%
1/3/2023Dawson James
Subscribe to MarketBeat All Access for the recommendation accuracy rating		J. Kolbert
Subscribe to MarketBeat All Access for the recommendation accuracy rating		DowngradeBuy ➝ Neutral
(Data available from 9/26/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












CANF Price Target - Frequently Asked Questions

What is Can-Fite BioPharma's consensus rating and price target?

According to the issued ratings of 2 analysts in the last year, the consensus rating for Can-Fite BioPharma stock is Moderate Buy based on the current 1 hold rating and 1 buy rating for CANF. The average twelve-month price prediction for Can-Fite BioPharma is $23.00 with a high price target of $34.00 and a low price target of $12.00. Learn more on CANF's analyst rating history.

Do Wall Street analysts like Can-Fite BioPharma more than its competitors?

Analysts like Can-Fite BioPharma less than other Medical companies. The consensus rating score for Can-Fite BioPharma is 2.50 while the average consensus rating score for medical companies is 2.66. Learn more on how CANF compares to other companies.

Does Can-Fite BioPharma's stock price have much upside?

According to analysts, Can-Fite BioPharma's stock has a predicted upside of 746.63% based on their 12-month price targets.

What analysts cover Can-Fite BioPharma?

Can-Fite BioPharma has been rated by Alliance Global Partners in the past 90 days.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NYSE:CANF) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -